$DCTH: NEWS~~Delcath Announces Agreement for Extinguishment

New Post Public Reply Private Reply Replies (1) Message Board
SHEEPWOLF
659
$DCTH: NEWS~~Delcath Announces Agreement for Extinguishment of Convertible Notes with Majority Holder

Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split Voting Deadline Extended to September 7, 2017

NEW YORK, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ CTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that the Company has negotiated an agreement for the extinguishment of its 2016 Convertible Notes from the holder of the majority of the Notes. The transaction is contingent upon the Company effecting a reverse stock split which requires shareholder approval through the current consent solicitation. If fully executed, the agreement will extinguish approximately 90% of the remaining $12.6 million in debt related to the Convertible Notes.

“We negotiated this agreement as a means of reducing future potential dilution from the Convertible Notes after a reverse stock split. We strongly urge shareholders to vote in favor of the proposed reverse stock split as it will now trigger the extinguishment of a substantial portion of the Convertible Notes. The proposed reverse stock split will also allow us to regain compliance with the Nasdaq Minimum Bid Price, which provides liquidity and other benefits to shareholders. Additionally, we believe a successful reverse stock split will provide the Company with the flexibility to raise new equity capital at potentially more beneficial terms, allowing us to continue to support our Clinical Development Program and commercial efforts in Europe where we believe shareholder value ultimately resides,” stated Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.

Under the terms of this new agreement, effective immediately, the Company’s Series A and B preferred shares will be redeemed and $1.65 million in restricted cash related to the Convertible Notes will be released to the Company. Following shareholder approval of the proposed reverse stock split, several additional transactions will occur to extinguish the Convertible Notes held by the majority Note Holder: the Note Holder shall release all restrictions on the $6.4 million of remaining restricted cash; the Note Holder shall redeem $4.0 million of Convertible Note; the Company and the Note Holder shall exchange $2.4 million of the remaining Convertible Notes for new warrants to purchase 40.0 million shares of Common Stock at an exercise price of $0.35. A final amount of $3.8 million in debt will remain outstanding until converted or redeemed in accordance with the original Convertible Note agreement. These transactions are estimated on a pre-split basis and will be subject to adjustment by the split ratio determined by its Board of Directors upon approval of the reverse split proposal.

A Vote in Favor of the Reverse Stock Split Proposal is Required to Trigger Extinguishment Agreement and Maintain Nasdaq Listing

If approved by the shareholders, a reverse stock split will bring the company’s stock price above $1.00 allowing the Company to meet NASDAQ’s minimum bid price requirement.

Should the Company not obtain approval for a reverse stock split, it is likely that the Company will be delisted from Nasdaq. Further, the Convertible Notes will not be extinguished because the Notes will likely be the primary or only source of funding once the Company is listed on an alternate market.

For these reasons, the Company’s Board of Directors encourages all shareholders to support the proposed reverse stock split. Shareholders are encouraged to read the Company’s Definitive Schedule 14A in detail for full information regarding the proposed reverse stock split.

Voting Deadline Extended to September 7, 2017 with Allowance to Change Consent

In order to properly consider this new information, the Company has amended its Consent Proposal materials to extend the consent deadline to September 7, 2017 and to permit shareholders to change their consents after initial submission by submitting a new consent form. Shareholders may also vote by calling (800) 454-8683 or by visiting www.proxyvote.com.

Proposal on Effecting a Reverse Stock Split

Delcath recently filed a Definitive Schedule 14A detailing a proposed reverse stock split, subject to shareholder approval. Delcath needs the ability to issue common shares to fund operations, support clinical programs, and explore alternative equity financing opportunities. However, the Company is currently at the maximum amount of authorized shares of common stock under its Certificate of Incorporation. Without a significant increase in available authorized shares, the Company is unable to undertake any type of equity financing. The proposed reverse stock split will reduce the number of shares outstanding and provide Delcath with the flexibility to raise equity capital and support its important clinical trials and commercial efforts in Europe.

In addition, the reverse stock split will allow Delcath to regain compliance with NASDAQ Capital Markets minimum bid price requirements, which provides liquidity and other important benefits to the Company and its investors.

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM), and plans to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC) by the end of 2017 contingent on effecting the reverse stock split as outlined in the Company’s consent proposal. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

Forward Looking Statements
Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials including without limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM clinical trial, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, our ability to maintain NASDAQ listing, and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact:
Scott Gordon
President - CoreIR
Email: investorrelations@delcath.com
Source: Delcath Systems, Inc.
© 2017 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/DCTH/news
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 28

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 57

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 68

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 77

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 84

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 50

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 133

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 107

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from BioRestorative's CEO on Regenerative Medicine

Updated Category News Views 168

CEO Lance Alstodt Discusses BioRestorative's Vision In a recent interview on “The Big Biz Show,” the dynamic CEO of BioRestorative Therapies, Inc., Lance Alstodt, shared invaluable insights into the company's journey. As a pioneer in regenerative medicine, BioRestorative focuses on innovative stem cell-based therapies aimed at addressing various medical challenges....

Continue Reading
Hargreave Hale AIM VCT PLC NAV Announcement

Updated Category News Views 73

Hargreave Hale AIM VCT PLC (the “Company”) Net Asset Value Announcement As of the close of business on 16 August 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc stands at: NAV per Ordinary share of 1p – 42.03 pence. Contact Information If you need more information, please reach out to: JTC (UK) Limited Uloma Adighibe Alexandria Tivey Email...

Continue Reading
Discover Luxury Living at Toll Brothers' New Community in Texas

Updated Category News Views 150

Introducing Toll Brothers at George's Ranch In a splendid showcase of luxury living, Toll Brothers, Inc. (NYSE:TOL) has unveiled its newest community, Toll Brothers at George's Ranch, located in the serene surroundings of Boerne, Texas. This exciting development marks an important addition to the San Antonio area, where elegance meets modern design. Grand Opening...

Continue Reading
xLean's TR1 Robot Revolutionizes Cleaning Technology

Updated Category News Views 224

xLean's Innovative TR1 Takes Center Stage xLean Robotics concluded an exciting showcase at IFA 2025, where its groundbreaking TR1, the world's first dual-form transformable floor washing robot, earned several prestigious awards. This innovative device was recognized as the 'Best in IFA Next Winner' and 'Best in Design Honoree,' and it was featured as one of the 'Top 5...

Continue Reading
Alpha Modus Sues H&M for Patent Infringement Regarding AI Tech

Updated Category News Views 165

Alpha Modus Files Patent Infringement Lawsuit Against H&M Alpha Modus, Corp. is making headlines for filing a substantial patent infringement lawsuit against H&M Fashion USA, Inc. in the United States District Court for the Eastern District of Texas, Marshall Division. This legal action centers around allegations that H&M's retail operations in the U.S. are infringing...

Continue Reading